Pre-Emptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-Free on Total Therapy 2 (UARK 98-026).

Trial Profile

Pre-Emptive Strike With Bortezomib (VELCADE) in Participants With Multiple Myeloma Still Event-Free on Total Therapy 2 (UARK 98-026).

Discontinued
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2011

At a glance

  • Drugs Bortezomib (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Mar 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 15 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top